Business
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy Demonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platform Expanded preclinical pipeline with large market geographic atrophy (GA) and alpha-1 antitrypsin deficiency lung disease (AATLD) programs On track for multiple clinical data updates on lead clinical-stage product candidates during 2023 Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, today announced full year 2022 financial results and provided operational highlights. “We are proud to have validated 4DMT’s Therapeutic Vector Evolution platform over the past year, with clinical efficacy proof-of-concept signals with all three of our lead proprietary vectors invented at 4DMT,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “We believe we’re primed to continue leveraging our robust product design and development engine to grow and diversify our product pipeline with seven total product candidates in development. Our five clinical-stage product candidates address unmet medical needs in seven patient populations, including several large and high incidence rate disease markets. Our capital-efficient operations and strong cash position are expected to support operations into the first half of 2025.” Recent Highlights Ophthalmology Therapeutic Area Significant progress advancing the 4D-150 program for the intravitreal treatment of patients with wet AMD and with DME Presented interim data from Cohort 1 (n=5) of Phase 1/2 PRISM clinical trial for wet AMD in November 2022; 4D-150 was demonstrated to be safe and well-tolerated, and resulted in >90% reduction in annualized anti-VEGF injection ratesCompleted enrollment of PRISM Dose Exploration stage (n=15, 3 dose levels); enrollment in Phase 2 Dose Expansion (n=50)...